20 results on '"Kilpatrick, Trevor"'
Search Results
2. Multiple sclerosis: Cognition and saccadic eye movements
- Author
-
Fielding, Joanne, Kilpatrick, Trevor, Millist, Lynette, and White, Owen
- Published
- 2009
- Full Text
- View/download PDF
3. Visceral leishmaniasis in a returned traveller on fingolimod therapy
- Author
-
Williams, Eloise, Kilpatrick, Trevor, Grigg, Andrew, Leroi, Marcel, and Kwong, Jason C.
- Published
- 2020
- Full Text
- View/download PDF
4. Fine mapping of multiple sclerosis susceptibility genes provides evidence of allelic heterogeneity at the IL2RA locus
- Author
-
Perera, Devindri, Stankovich, Jim, Butzkueven, Helmut, Taylor, Bruce V., Foote, Simon J., Kilpatrick, Trevor J., and Rubio, Justin P.
- Published
- 2009
- Full Text
- View/download PDF
5. Impact of telehealth on health care in a multiple sclerosis outpatient clinic during the COVID-19 pandemic.
- Author
-
Li, Vivien, Roos, Izanne, Monif, Mastura, Malpas, Charles, Roberts, Stefanie, Marriott, Mark, Buzzard, Katherine, Nguyen, Ai-Lan, Seery, Nabil, Taylor, Lisa, Kalincik, Tomas, and Kilpatrick, Trevor
- Abstract
• Patient satisfaction with telehealth was high with video consultations preferred. • Clinicians strongly preferred in-person visits which allow physical examination. • Telehealth-based EDSS was feasible but may under-estimate lower EDSS. • Treatment inertia may affect management decisions during telehealth consultations. The coronavirus disease 2019 (COVID-19) pandemic has precipitated expansion of telemedicine in outpatient management of chronic diseases including multiple sclerosis (MS). Studies conducted pre-pandemic, when telehealth was an alternative to in-person consultations, represent a different setting to current practice. The aim of this study was to assess the impact of telehealth on MS outpatient care in a tertiary metropolitan hospital in Melbourne, Australia during the COVID-19 pandemic. From March-December 2020, patients and clinicians in the MS outpatient clinic were surveyed regarding their attitudes towards telehealth. Scores on the Expanded Disability Status Scale (EDSS) from telehealth and face-to-face appointments during the study period were compared to scores from face-to-face consultations before and after this period. Medical records were reviewed to compare management decisions made during telehealth versus face-to-face consultations. Diagnoses and treatment of MS relapses were compared to 2019. Telehealth was used in 73% of outpatient appointments. Patient satisfaction was generally high. Patients and clinicians preferred face-to-face consultations but were willing to use telehealth longer term. Overall, there were no significant delays in identifying patients experiencing disability worsening via telehealth, but EDSS increase was recorded in more face-to-face than telehealth appointments particularly for those with lower baseline disability. Disease-modifying therapy commencement rates were similar, but symptomatic therapy initiation and investigation requests occurred more frequently in face-to-face visits. Comparable numbers of MS relapses were diagnosed and treated with corticosteroids in 2019 and 2020. Patient satisfaction with telehealth was high, but both clinicians and patients preferred in-person appointments. Telehealth implementation did not lead to high rates of undetected disability worsening or undiagnosed acute relapses, but telehealth-based EDSS assessment may underestimate lower scores. Treatment inertia may affect some management decisions during telehealth consultations. Telehealth will likely play a role in outpatient settings beyond the COVID-19 pandemic with further studies on its long-term impact on clinical outcomes required. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy.
- Author
-
Broadley, Simon A., Barnett, Michael H., Boggild, Mike, Brew, Bruce J., Butzkueven, Helmut, Heard, Robert, Hodgkinson, Suzanne, Kermode, Allan G., Lechner-Scott, Jeannette, Macdonell, Richard A.L., Marriott, Mark, Mason, Deborah F., Parratt, John, Reddel, Stephen W., Shaw, Cameron P., Slee, Mark, Spies, Judith, Taylor, Bruce V., Carroll, William M., and Kilpatrick, Trevor J.
- Abstract
In Part 2 of this three part review of multiple sclerosis (MS) treatment with a particular focus on the Australian and New Zealand perspective, we review the newer therapies that have recently become available and emerging therapies that have now completed phase III clinical trial programs. We go on to compare the relative efficacies of these newer and emerging therapies alongside the existing therapies. The effectiveness of β-interferon in the treatment of different stages and the different disease courses of MS is critically reviewed with the conclusion that the absolute level of response in term of annualised relapse rates (where relapses occur) and MRI activity are similar, but are disappointing in terms of sustained disability progression for progressive forms of the disease. Finally we review the controversial area of combination therapy for MS. Whilst it remains the case that we have no cure or means of preventing MS, we do have a range of effective therapies that when used appropriately and early in the disease course can have a significant impact on short term and longer term outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
7. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations.
- Author
-
Broadley, Simon A., Barnett, Michael H., Boggild, Mike, Brew, Bruce J., Butzkueven, Helmut, Heard, Robert, Hodgkinson, Suzanne, Kermode, Allan G., Lechner-Scott, Jeannette, Macdonell, Richard A.L., Marriott, Mark, Mason, Deborah F., Parratt, John, Reddel, Stephen W., Shaw, Cameron P., Slee, Mark, Spies, Judith, Taylor, Bruce V., Carroll, William M., and Kilpatrick, Trevor J.
- Abstract
In this third and final part of our review of multiple sclerosis (MS) treatment we look at the practical day-to-day management issues that are likely to influence individual treatment decisions. Whilst efficacy is clearly of considerable importance, tolerability and the potential for adverse effects often play a significant role in informing individual patient decisions. Here we review the issues surrounding switching between therapies, and the evidence to assist guiding the choice of therapy to change to and when to change. We review the current level of evidence with regards to the management of women in their child-bearing years with regards to recommendations about treatment during pregnancy and whilst breast feeding. We provide a summary of recommended pre- and post-treatment monitoring for the available therapies and review the evidence with regards to the value of testing for antibodies which are known to be neutralising for some therapies. We review the occurrence of adverse events, both the more common and troublesome effects and those that are less common but have potentially much more serious outcomes. Ways of mitigating these risks and managing the more troublesome adverse effects are also reviewed. Finally, we make specific recommendations with regards to the treatment of MS. It is an exciting time in the world of MS neurology and the prospects for further advances in coming years are high. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
8. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies.
- Author
-
Broadley, Simon A., Barnett, Michael H., Boggild, Mike, Brew, Bruce J., Butzkueven, Helmut, Heard, Robert, Hodgkinson, Suzanne, Kermode, Allan G., Lechner-Scott, Jeannette, Macdonell, Richard A.L., Marriott, Mark, Mason, Deborah F., Parratt, John, Reddel, Stephen W., Shaw, Cameron P., Slee, Mark, Spies, Judith, Taylor, Bruce V., Carroll, William M., and Kilpatrick, Trevor J.
- Abstract
Multiple sclerosis (MS) is a potentially life-changing immune mediated disease of the central nervous system. Until recently, treatment has been largely confined to acute treatment of relapses, symptomatic therapies and rehabilitation. Through persistent efforts of dedicated physicians and scientists around the globe for 160 years, a number of therapies that have an impact on the long term outcome of the disease have emerged over the past 20 years. In this three part series we review the practicalities, benefits and potential hazards of each of the currently available and emerging treatment options for MS. We pay particular attention to ways of abrogating the risks of these therapies and provide advice on the most appropriate indications for using individual therapies. In Part 1 we review the history of the development of MS therapies and its connection with the underlying immunobiology of the disease. The established therapies for MS are reviewed in detail and their current availability and indications in Australia and New Zealand are summarised. We examine the evidence to support their use in the treatment of MS. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. Subjective versus objective performance in people with multiple sclerosis using the MSReactor computerised cognitive tests.
- Author
-
Merlo, Daniel, Kalincik, Tomas, Zhu, Chao, Gresle, Melissa, Lechner-Scott, Jeannette, Kilpatrick, Trevor, Barnett, Michael, Taylor, Bruce, Buzzard, Katherine, Darby, David, Butzkueven, Helmut, and van der Walt, Anneke
- Abstract
Perceived cognitive impairment in MS is associated with adverse changes in employment capacity, sexual function, and aspects of daily living. Studies have shown relationships between perceived cognitive impairment and objective neuropsychological functioning and mood. Subjective cognitive performance in people with MS has not previously been compared to their objective performance on a computerised cognitive battery. All participants completed at least 6-monthly serial testing on the MSReactor computerised cognitive testing platform consisting of 3 reaction time tasks. These measure psychomotor processing speed (simple reaction time), attention (choice reaction time) and working memory (One back task). In addition, we collected subjective cognitive performance and patient reported outcomes of depression, anxiety and quality of life. The strength and direction of the relationships between subjective and objective performance on the cognitive tasks were examined using Kendalls rank coefficient at year 1 and year 2. We calculated partial correlation estimates where subjective performance was also associated with patient reported outcomes. Subjective overall performance correlated weakly with the working memory task (Tau -0.10; (95% confidence interval (CI) -0.19, -0.01). Subjective performance also correlated weakly with depression but not anxiety or quality of life. Subjective reaction speed correlated weakly with psychomotor processing speed (Tau -0.10; CI -0.19, -0.01); and subjective accuracy correlated weakly with the attention (Tau 0.12; CI 0.03, 0.21) and working memory (Tau 0.15; CI 0.05, 0.24) tasks, respectively. Participants' perceived performance on the MSReactor tests correlated only weakly with objective changes. Depression was associated with subjective cognitive performance reports. These results suggest that a person with MS' perception of their cognitive performance is only weakly associated with cognitive changes detected using MSReactor. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Control of visually guided saccades in multiple sclerosis: Disruption to higher-order processes
- Author
-
Fielding, Joanne, Kilpatrick, Trevor, Millist, Lynette, and White, Owen
- Subjects
- *
SACCADIC eye movements , *MULTIPLE sclerosis , *EYE movement disorders , *CELL death , *BRAIN stem , *NEURAL circuitry , *PATIENTS - Abstract
Abstract: Ocular motor abnormalities are a common feature of multiple sclerosis (MS), with more salient deficits reflecting tissue damage within brainstem and cerebellar circuits. However, MS may also result in disruption to higher level or cognitive control processes governing eye movement, including attentional processes that enhance the neural processing of behaviourally relevant information. The attentional control of eye movement was investigated in 25 individuals with MS and a comparable number of neurologically healthy individuals matched for age and IQ. This entailed an evaluation of distractor-related effects on the generation of both unpredictable and predictable visually guided saccades, as well as an evaluation of the effects of presenting endogenous cues prior to target onset. For unpredictable saccades, we revealed an exaggerated distractor effect in MS, with saccade latencies prolonged and endpoints less accurate in the presence of a visual distractor. Predictable saccades tended to be hypometric for MS patients, although we found no significant distractor effects. For endogenously cued saccades, we found no group differences in latency following a valid cue, but an exaggerated increase in latency following invalid cues for MS patients. MS patients also generated a significantly greater proportion of erroneous responses to cue stimuli. These ocular motor characteristics demonstrate considerable sensitivity with respect to evaluating attentional deficits in MS, evident even in the absence of clinical signs of disease. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
11. Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia.
- Author
-
Seery, Nabil, Li, Vivien, Nguyen, Ai-Lan, Roos, Izanne, Buzzard, Katherine A, Atvars, Roberts, Taylor, Nicola, Tunnell, Kelsey, Carey, John, Dwyer, Chris, Taylor, Hasini Fernandoa Lisa, Baker, Josephine, Marriott, Mark P, Kilpatrick, Trevor J, Kalincik, Tomas, and Monif, Mastura
- Abstract
• Covid-19 pandemic can have implications for MS and neuroimmunology patients and potentially their adherence to disease modifying therapies (DMTs). • A large proportion of patients receiving DMT's for their MS expressed some degree of concern regarding the COVID-19 pandemic and their therapy in one MS centre in Australia. • The level of concern in most patients was at most mild however. • Patients ascribed similar concern to the risk of a relapse of their disease compared to the risk of contracting COVID-19, perhaps underscoring a willingness to continue their DMT despite the pandemic. Objective: Patients with Multiple Sclerosis (MS) and on disease modifying therapies (DMTs) that can be immunosuppressive or immunomodulatory form a special group where risk of continuation of DMT needs to be taken into account with risk of contracting Covid-19. This concept can pose a degree of anxiety for patients as well as neurologists. We aimed to evaluate patient perspectives regarding the use of Natalizumab and anti-CD20 therapies (Rituximab and Ocrelizumab) in the context of the COVID-19 pandemic. Methods: cross-sectional study conducted via voluntary survey filled in by patients with MS and related disorders receiving their infusional treatment in one MS centre in Australia, exploring their concerns regarding their therapy, their therapy and COVID-19, precautions undertaken in response to the pandemic, and factors impacting their decision-making. Results: 170 patients completed the survey. Of patients on Natalizumab, the majority had either no or mild concern regarding their DMT and COVID-19, and of patients on B-cell depleting therapies, again, the majority had no or mild concern, though a slightly higher proportion had a moderate level of concern. Asked to delineate their concerns, an increased risk of contracting COVID-19 was more commonly conveyed than MS-specific factors or poor outcomes pertaining to COVID-19 if contracted, by patients in both groups. Conversely, being invited to specifically consider the possibility of contracting COVID-19 or experience a relapse of MS, almost half of the cohort rated both of equal of concern. More than half of the cohort were self-isolating more stringently than general government advice and government-related resources followed by information provided by patient's neurologist where the commonest means of information to guide decision making. Conclusions: Whilst a large proportion of patients had some concern regarding the impact of their DMT on COVID-19, whether on their risk of contracting COVID-19 or a theoretical risk for more severe disease, the overall level of concern in most cases was at most mild. Patients on B-cell depleting therapies were more inclined to express a higher level of concern. A similar concern was ascribed to a risk of a relapse or worsening MS symptoms compared to the risk of contracting COVID-19. Such attitudes may underscore a willingness of patients to continue their DMT where benefits outweigh risks during future phases of the COVID-19 pandemic. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing-remitting multiple sclerosis.
- Author
-
Yam, Charmaine, Merlo, Daniel, Stankovich, Jim, Darby, David, Gresle, Melissa, Kalincik, Tomas, Kilpatrick, Trevor J., Lechner-Scott, Jeanette, Taylor, Bruce, Barnett, Michael, Butzkueven, Helmut, and van der Walt, Anneke
- Abstract
• The MSReactor battery could monitor for cognitive change in the clinic setting. • MSReactor battery correlates moderately with the Processing Speed Test. • The test-retest reliability was good for both tests over 6 months. • Depression and anxiety have minimal effect on MSReactor scores. • Manual dexterity has no effect on MSReactor and Processing Speed test scores. Monitoring and screening of cognitive function in the ambulatory setting requires simple, brief cognitive tests that are reproducible. MSReactor (MSR) is a web-based platform that screens psychomotor (processing) speed, attention and working memory using a game-like interface. The Processing Speed Test (PST) is a validated computerized version of the Symbol Digit Modalities test (SDMT) and component of the Multiple Sclerosis Performance Test (MSPT). To determine the baseline and 6-month predictive correlations between the MSReactor computerised cognitive battery and the PST. Prospectively enrolled relapsing-remitting multiple sclerosis (RRMS) patients completed the MSR and the PST during 6-monthly clinic visits. Pearson's product-moment coefficients with partial correlation adjustment were calculated between the PST and MSR reaction times for Simple reaction test (SRT), Choice reaction test (CRT) and One- back test (OBK). 379 RRMS patients from six tertiary MS centres in Australia were enrolled. The mean age was 40.4 years (SD 10.3) and median Expanded Disability Status Scale (EDSS) score was 1.5 (IQR 1.0 – 2.0). Most (66%) were on high efficacy disease-modifying treatment. Baseline PST scores correlated with the MSR reaction times: SRT (R =-0.40), CRT (R = -0.44) and OBK (R = -0.47), p <0.05. There was a moderate correlation between the first visit MSR and 6-month PST test for SRT (R = -0.37, p <0.001), CRT (R =-0.44, p < 0.001) and OBK (R = -0.43, p < 0.001) speed. MSR-measured psychomotor speed, attention and working memory at baseline moderately correlates with baseline and 6-month PST; suggesting overlapping cognitive processes are being tested. Six-month test-retest reliability was acceptable for both tests. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Paraclinical Correlates of Visual Acuity Loss in Multiple Sclerosis.
- Author
-
Marriott, Mark, Kolbe, Scott C, Butzkueven, Helmut, Kilpatrick, Trevor J, and Egan, Gary F
- Published
- 2009
- Full Text
- View/download PDF
14. 89. Modulation of regulatory and cytotoxic T cell expression signature in first demyelinating events and early multiple sclerosis.
- Author
-
Skibina, Olga G., Perreau, Victoria M., Hu, Yifang, Binder, Michele, Judith, Judith, Butzkueven, Helmut, Smyth, Gordon, and Kilpatrick, Trevor
- Published
- 2010
- Full Text
- View/download PDF
15. 29. Probing neuron-glial interactions for therapeutic benefit.
- Author
-
Kilpatrick, Trevor
- Published
- 2010
- Full Text
- View/download PDF
16. Vitamin D status: Multifactorial contribution of environment, genes and other factors in healthy Australian adults across a latitude gradient.
- Author
-
Lucas, Robyn M., Ponsonby, Anne-Louise, Dear, Keith, Valery, Patricia C., Taylor, Bruce, van der Mei, Ingrid, McMichael, Anthony J., Pender, Michael P., Chapman, Caron, Coulthard, Alan, Kilpatrick, Trevor J., Stankovich, Jim, Williams, David, and Dwyer, Terence
- Subjects
- *
VITAMIN D deficiency , *PHENOTYPES , *BLOOD sampling , *PHYSIOLOGICAL effects of ultraviolet radiation , *CROSS-sectional method , *BIOMARKERS - Abstract
Vitamin D deficiency is common and implicated in risk of several human diseases. Evidence on the relative quantitative contribution of environmental, genetic and phenotypic factors to vitamin D status (assessed by the serum concentration of 25-hydroxyvitamin D, 25(OH)D) in free-living populations is sparse. We conducted a cross-sectional study of 494 Caucasian adults aged 18–61years, randomly selected from the Australian Electoral Roll according to groups defined by age, sex and region (spanning 27°–43°South). Data collected included personal characteristics, sun exposure behaviour, biomarkers of skin type and past sun exposure, serum 25(OH)D concentration and candidate single nucleotide polymorphisms. Ambient ultraviolet radiation (UVR) levels in the month six weeks before blood sampling best predicted vitamin D status. Serum 25(OH)D concentration increased by 10nmol/L as reported time in the sun doubled. Overall, 54% of the variation in serum 25(OH)D concentration could be accounted for: 36% of the variation was explained by sun exposure-related factors; 14% by genetic factors (including epistasis) and 3.5% by direct measures of skin phenotype. Novel findings from this study are demonstration of gene epistasis, and quantification of the relative contribution of a wide range of environmental, constitutional and genetic factors to vitamin D status. Ambient UVR levels and time in the sun were of prime importance but it is nonetheless important to include the contribution of genetic factors when considering sun exposure effects. This article is part of a Special Issue entitled ‘Vitamin D Workshop’. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
17. Therapeutic potential of LIF in multiple sclerosis
- Author
-
Slaets, Helena, Hendriks, Jerome J.A., Stinissen, Piet, Kilpatrick, Trevor J., and Hellings, Niels
- Subjects
- *
MULTIPLE sclerosis treatment , *DISEASE relapse , *LEUKEMIA inhibitory factor , *CYTOKINES , *IMMUNOLOGICAL adjuvants , *TREATMENT of neurodegeneration , *DEMYELINATION , *PREVENTION - Abstract
Therapies for multiple sclerosis (MS) reduce the relapse rate but are unable to stop neurological decline. Here, we evaluate the potential of leukemia inhibitory factor (LIF) as a novel therapeutic in diseases with a neurodegenerative and inflammatory component, such as MS. LIF, which can be a proinflammatory cytokine, can also modulate the immune response in a beneficial way. Recent evidence demonstrates a crucial role of LIF in neuroprotection and axonal regeneration as well as the prevention of demyelination. Finally, LIF is an important survival factor for stem cells and neuronal precursors. Therefore, we propose that LIF is a potential therapeutic candidate for MS. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
18. Influence of methylprednisolone on magnetic resonance and histological measures during cuprizone-induced demyelination
- Author
-
Cate, Holly S., Wu, Qi-Zhu, Kemper, Dennis, Merlo, Daniel, Wang, Hong-Xin, Fang, Ke, Egan, Gary F., and Kilpatrick, Trevor J.
- Subjects
- *
MAGNETIC resonance imaging of the brain , *GLUCOCORTICOIDS , *HISTOLOGY , *DEMYELINATION , *LABORATORY mice , *QUANTITATIVE research , *BRAIN injury diagnosis - Abstract
Abstract: MRI is widely used for routine assessment of the progression of white matter injury while patients receive therapeutic agents, such as the glucocorticoid agonist methylprednisolone (MP). Given this, it is important to determine whether MRI parameters are altered by MP treatment in the absence of changes in cellular and myelin pathology. In this study, we compared magnetic resonance and histological measures during myelin injury in mice with and without short duration MP administration. Mice were scanned with a 4.7T MRI scanner before and after MP or vehicle injections using T2WI and DTI sequences and histology was performed on the brains following the second scan. Comparison of post-injection to pre-injection MRI showed a reduced T2WI intensity in the CC and an attenuated response in ADC|| and ADC⊥ in the MP group in comparison with the vehicle group. However, quantitative analyses of myelin staining, neurofilament intensity and oligodendrocyte and microglial density were not different between the MP and the vehicle groups, indicating that the short duration MP treatment did not alter cellular and myelin pathology. These data suggest that MP could confound the validity of paraclinical measures such as ADC|| and ADC⊥ that are otherwise being touted as markers of either axonal integrity or myelin repair. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
19. Neuroprotection in multiple sclerosis: A therapeutic challenge for the next decade
- Author
-
Van der Walt, Anneke, Butzkueven, Helmut, Kolbe, Scott, Marriott, Mark, Alexandrou, Estella, Gresle, Melissa, Egan, Gary, and Kilpatrick, Trevor
- Subjects
- *
MULTIPLE sclerosis treatment , *NEUROPROTECTIVE agents , *AUTOIMMUNE diseases , *CAUCASIAN race , *CENTRAL nervous system , *NEURODEGENERATION , *INFLAMMATION , *RANDOMIZED controlled trials - Abstract
Abstract: Multiple sclerosis (MS) is the commonest cause of progressive neurological disability amongst young, Caucasian adults. MS is considered to be an auto-immune disease that results from an attack against myelin, the layer which surrounds axons. The pathophysiology of MS is complex, with both demyelination and axonal degeneration contributing to what is essentially an inflammatory neurodegenerative disease. Axonal loss is increasingly being accepted as the histopathological correlate of neurological disability. Currently, the underpinnings of neurodegeneration in MS, and how to promote neuroprotection are only partly understood. No established treatments that directly reduce nervous system damage or enhance its repair are currently available. Moreover, the ability of currently available immunomodulatory therapies used to treat MS, such as interferon-β, to prevent long-term disability is uncertain. Results from short-term randomized-controlled trials suggest a partial benefit with regards to disability outcomes, but this is yet to be established in long-term studies. Novel neuroprotective agents have been identified in preclinical studies but their development is being hampered by the absence of appropriate clinical platforms to test them. In this article, we will discuss some of the principal therapeutic candidates that could provide neuroprotection in MS and emerging methodologies by which to test them. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
20. Development of [18F]MIPS15692, a radiotracer with in vitro proof-of-concept for the imaging of MER tyrosine kinase (MERTK) in neuroinflammatory disease.
- Author
-
Wong, Siu Wai, Vivash, Lucy, Mudududdla, Ramesh, Nguyen, Nghi, Hermans, Stefan J., Shackleford, David M., Field, Judith, Xue, Lian, Aprico, Andrea, Hancock, Nancy C., Haskali, Mohammad, Stashko, Michael A., Frye, Stephen V., Wang, Xiaodong, Binder, Michele D., Ackermann, Uwe, Parker, Michael W., Kilpatrick, Trevor J., and Baell, Jonathan B.
- Subjects
- *
RADIOACTIVE tracers , *PROTEIN-tyrosine kinases , *POSITRON emission tomography , *RADIOCHEMICAL purification , *LABORATORY mice , *X-ray crystallography - Abstract
MER tyrosine kinase (MERTK) upregulation is associated with M2 polarization of microglia, which plays a vital role in neuroregeneration following damage induced by neuroinflammatory diseases such as multiple sclerosis (MS). Therefore, a radiotracer specific for MERTK could be of great utility in the clinical management of MS, for the detection and differentiation of neuroregenerative and neurodegenerative processes. This study aimed to develop an [18F] ligand with high affinity and selectivity for MERTK as a potential positron emission tomography (PET) radiotracer. MIPS15691 and MIPS15692 were synthesized and kinase assays were utilized to determine potency and selectivity for MERTK. Both compounds were shown to be potent against MERTK, with respective IC 50 values of 4.6 nM and 4.0 nM, and were also MERTK-selective. Plasma and brain pharmacokinetics were measured in mice and led to selection of MIPS15692 over MIPS15691. X-ray crystallography was used to visualize how MIPS15692 is recognized by the enzyme. [18F]MIPS15692 was synthesized using an automated iPHASE FlexLab module, with a molar activity (A m) of 49 ± 26 GBq/μmol. The radiochemical purity of [18F]MIPS15692 was >99% and the decay-corrected radiochemical yields (RCYs) were determined as 2.45 ± 0.85%. Brain MERTK protein density was measured by a saturation binding assay in the brain slices of a cuprizone mouse model of MS. High levels of specific binding of [18F]MIPS15692 to MERTK were found, especially in the corpus callosum/hippocampus (CC/HC). The in vivo PET imaging study of [18F]MIPS15692 suggested that its neuroPK is sub-optimal for clinical use. Current efforts are underway to optimize the neuroPK of our next generation PET radiotracers for maximal in vivo utility. [Display omitted] • MIPS15692 showed high potency (4 nM) and ∼28 fold selectivity to MERTK over FLT3. • Crystal structure of MIPS15692 complexed with MERTK at 3.06 Å resolution (PDB: 7M5Z). • [18F]MIPS15692 showed specific binding to MERTK in MS murine model in autoradiography. • First time that a [18F]radiotracer has signalled for MERTK in a disease animal model. • First time the B max for MERTK has been determined in brain of a MS animal model. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.